WHO ICTRP trial
Study to evaluate the Safety and Early Effects of Tinodasertib in People who are…
ACTRN12625000887471 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Recruiting
Key facts
| Trial ID | ACTRN12625000887471 |
|---|---|
| Public title | Study to evaluate the Safety and Early Effects of Tinodasertib in People who are overweight or Have Obesity. |
| Scientific title | A Phase Ib, Double-Blind, Randomised, Placebo-Controlled, Parallel Design, Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tinodasertib Monotherapy in Subjects with Obesity or who are Overweight. |
| Primary sponsor | Karyogen |
| Secondary sponsors | AUM Biosciences |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | Australia |
| Conditions | Obesity; Obesity;Metabolic and Endocrine - Metabolic disorders;Diet and Nutrition - Obesity |
| Interventions | This study is a Phase 1b, single center, randomised, placebo-controlled, double-blind, parallel design study to assess the safety and tolerability of 3 doses of tinodasertib administered daily orally compared with placebo for weight… |
| Registration date | Aug 15, 2025 |
| Target size | 64 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: